ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride → HCID 86753058, compound
Reaction equation
Cl.[CH2:2]([N:4]([CH2:9][C:10]1[C:15]([N+:16]([O-])=O)=[CH:14][CH:13]=[C:12]([Cl:19])[C:11]=1[Cl:20])[CH2:5][C:6]([OH:8])=[O:7])[CH3:3].C1C2N=C3N(CC=2C(Cl)=C(Cl)C=1)CC(=O)N3.Cl[Sn]Cl.Cl>>[ClH:19].[CH2:2]([N:4]([CH2:9][C:10]1[C:15]([NH2:16])=[CH:14][CH:13]=[C:12]([Cl:19])[C:11]=1[Cl:20])[CH2:5][C:6]([OH:8])=[O:7])[CH3:3]Participants
Procedure
The ethyl-N-(2,3-dichloro-6-nitro benzyl) glycine HCl prepared above was used to make Anagrelide by known reactions. Firstly, the ethyl-N-(2,3-dichloro-6-nitro benzyl) glycine HCl is reacted with SnCl2 /HCl to form ethyl-N-(2,3-dichloro-6-amino benzyl) glycine HCl. This material is then reacted with CNBr in an inert, aprotic organic solvent such as toluene or chlorobenzene. The formed ethyl-N-(5,6-dichloro-3,4-dihydro-2(1 H) iminoguinazoline-3-acetate HCl is isolated and then reacted with a base such as triethanolamine (TEA) to form Anagrelide. This synthesis process is shown in U.S. Pat. No. 4,146,718, supra. The Anagrelide product produced had the characteristic pharmaceutical properties of commercially available Anagrelide made using for example, the present prior art synthesis process as described above.
Sources & evidence
- ORD record
- ord-538979e87d39453fa35983b3942b1728
- Source dataset
- uspto-grants-1998_09
- Patent number
- US05801245
Reaction notes
Loading…